12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Exelixis preclinical data

Researchers at the University of California, San Francisco, Pfizer Inc. (NYSE:PFE, New York, N.Y.) and Exelixis reported data from mouse models of pancreatic cancer showing that simultaneous inhibition of c-Met and VEGF signaling reduced tumor invasiveness and metastasis, whereas inhibiting VEGF signaling alone increased invasion and metastasis of tumors. Specifically, mice with pancreatic...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >